Efficacy and Safety of Nonantibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study) A Multicentre, Randomised, Open-label, Noninferiority Trial

被引:36
|
作者
Mora-Lopez, Laura [1 ]
Ruiz-Edo, Neus [1 ]
Estrada-Ferrer, Oscar [2 ]
Luisa Pinana-Campon, Maria [3 ]
Labro-Ciurans, Meritxell [4 ]
Escuder-Perez, Jordi [5 ]
Sales-Mallafre, Ricard [6 ]
Rebasa-Cladera, Pere [1 ]
Navarro-Soto, Salvador [1 ]
Serra-Aracil, Xavier [1 ]
机构
[1] Univ Autonoma Barcelona, Coloproctol Unit, Parc Tauli Univ Hosp,Dept Surg, Sabadell,Inst Invest & Innovacio,Parc Tauli I3PT, Barcelona, Spain
[2] Mataro Hosp, Coloproctol Unit, Mataro, Spain
[3] Hosp Univ St Joan Reus, Dept Surg, Reus, Spain
[4] Hosp St Joan de Deu Manresa, Dept Surg, Manresa, Spain
[5] Joan XXIII Univ Hosp, Coloproctol Unit, Tarragona, Spain
[6] Hosp St Pau & Santa Tecla, Santa Tecla, El Salvador
关键词
mild acute diverticulitis; nonantibiotic in acute diverticulitis; outpatient in acute diverticulitis; MODIFIED NEFF CLASSIFICATION; CLINICAL-TRIAL; ANTIBIOTICS; MANAGEMENT;
D O I
10.1097/SLA.0000000000005031
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Mild AD can be treated safely and effectively on an outpatient basis without antibiotics. Summary of Background Data: In recent years, it has shown no benefit of antibiotics in the treatment of uncomplicated AD in hospitalized patients. Also, outpatient treatment of uncomplicated AD has been shown to be safe and effective. Methods: A Prospective, multicentre, open-label, noninferiority, randomized controlled trial, in 15 hospitals of patients consulting the emergency department with symptoms compatible with AD. The Participants were patients with mild AD diagnosed by Computed Tomography meeting the inclusion criteria were randomly assigned to control arm (ATB-Group): classical treatment (875/125 mg/8 h amoxicillin/clavulanic acid apart from anti-inflammatory and symptomatic treatment) or experimental arm (Non-ATB-Group): experimental treatment (antiinflammatory and symptomatic treatment). Clinical controls were performed at 2, 7, 30, and 90 days. The primary endpoint was hospital admission. Secondary endpoints included number of emergency department revisits, pain control and emergency surgery in the different arms. Results: Four hundred and eighty patients meeting the inclusion criteria were randomly assigned to Non-ATB-Group (n = 242) or ATB-Group (n = 238). Hospitalization rates were: ATB-Group 14/238 (5.8%) and Non-ATB-Group 8/242 (3.3%) [mean difference 2.58%, 95% confidence interval (CI) 6.32 to -1.17], confirming noninferiority margin. Revisits: ATB-Group 16/238 (6.7%) and Non-ATB-Group 17/242 (7%) (mean difference -0.3, 95% CI 4.22 to -4.83). Poor pain control at 2 days follow up: ATB-Group 13/230 (5.7%), Non-ATB-Group 5/221 (2.3%) (mean difference 3.39, 95% CI 6.96 to -0.18). Conclusions: Nonantibiotic outpatient treatment of mild AD is safe and effective and is not inferior to current standard treatment.
引用
收藏
页码:E435 / E442
页数:8
相关论文
共 50 条
  • [21] Early noninvasive ventilation in general wards for acute respiratory failure: an international, multicentre, open-label, randomised trial
    Monti, Giacomo
    Cabrini, Luca
    Kotani, Yuki
    Brusasco, Claudia
    Kadralinova, Assiya
    Giardina, Giuseppe
    Chalkias, Athanasios
    Nakhnoukh, Cristina
    Pantazopoulos, Ioannis
    Oliva, Federico Mattia
    Dazzi, Federico
    Roasio, Agostino
    Redaelli, Martina Baiardo
    Tripodi, Vincenzo Francesco
    Cucciolini, Giada
    Belletti, Alessandro
    Vaschetto, Rosanna
    Maj, Giulia
    Borghi, Giovanni
    Savelli, Francesco
    Boni, Silvia
    D'Amico, Filippo
    Cavallero, Sarah
    Labanca, Rosa
    Tresoldi, Moreno
    Marmiere, Marilena
    Marzaroli, Matteo
    Moizo, Elena
    Monaco, Fabrizio
    Nardelli, Pasquale
    Pieri, Marina
    Plumari, Valentina
    Scandroglio, Anna Mara
    Turi, Stefano
    Corradi, Francesco
    Konkayev, Aidos
    Landoni, Giovanni
    Bellomo, Rinaldo
    Zangrillo, Alberto
    BRITISH JOURNAL OF ANAESTHESIA, 2025, 134 (02) : 382 - 391
  • [22] Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol
    Iwaki, Michihiro
    Kobayashi, Takashi
    Nogami, Asako
    Ogawa, Yuji
    Imajo, Kento
    Sakai, Eiji
    Nakada, Yoshinobu
    Koyama, Satoshi
    Kurihashi, Takeo
    Oza, Noriko
    Kohira, Toshikazu
    Okada, Michiaki
    Yamaguchi, Yuki
    Iwane, Shinji
    Kageyama, Fujito
    Sasada, Yuzo
    Matsushita, Masahiro
    Tadauchi, Akimitsu
    Murohisa, Gou
    Nagasawa, Masamichi
    Sato, Shuichi
    Maeda, Kazuhisa
    Furuta, Koichiro
    Shigefuku, Ryuta
    Seko, Yuya
    Tobita, Hiroshi
    Kawata, Kazuhito
    Kawanaka, Miwa
    Sugihara, Takaaki
    Tamaki, Nobuharu
    Iwasa, Motoh
    Kawaguchi, Takumi
    Itoh, Yoshito
    Kawaguchi, Atsushi
    Takahashi, Hirokazu
    Nakajima, Atsushi
    Yoneda, Masato
    BMJ OPEN, 2024, 14 (11):
  • [23] Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial
    van der Steen, Wouter
    de Graaf, Rob A. van
    Chalos, Vicky
    Lingsma, Hester F.
    van Doormaal, Pieter Jan
    Coutinho, Jonathan M.
    Emmer, Bart J.
    de Ridder, Inger
    van Zwam, Wim
    van der Worp, H. Bart
    van der Schaaf, Irene
    Gons, Rob A. R.
    Yo, Lonneke S. F.
    Boiten, Jelis
    van den Wijngaard, Ido
    Hofmeijer, Jeannette
    Martens, Jasper
    Schonewille, Wouter
    Vos, Jan Albert
    Tuladhar, Anil Man
    de Laat, Karlijn F.
    van Hasselt, Boudewijn
    Remmers, Michel
    Vos, Douwe
    Rozeman, Anouk
    Elgersma, Otto
    Uyttenboogaart, Maarten
    Bokkers, Reinoud P. H.
    van Tuijl, Julia
    Boukrab, Issam
    van den Berg, Reneprime
    Beenen, Ludo F. M.
    Roosendaal, Stefan D.
    Postma, Alida Annechien
    Krietemeijer, Menno
    Lycklama, Geert
    Meijer, Frederick J. A.
    Hammer, Sebastiaan
    van der Hoorn, Anouk
    Yoo, Albert J.
    Gerrits, Dick
    Truijman, Martine T. B.
    Zinkstok, Sanne
    Koudstaal, Peter J.
    Manschot, Sanne
    Kerkhoff, Henk
    Nieboer, Daan
    Berkhemer, Olvert
    Wolff, Lennard
    van der Sluijs, P. Matthijs
    LANCET, 2022, 399 (10329): : 1059 - 1069
  • [24] AN OPEN-LABEL, NONCOMPARATIVE STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF AZITHROMYCIN IN THE TREATMENT OF PATIENTS WITH ACUTE SINUSITIS
    AMIN, NM
    BREADON, G
    CLINICAL THERAPEUTICS, 1995, 17 (04) : 701 - 707
  • [25] A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis
    Barrager, E
    Veltmann, JR
    Schauss, AG
    Schiller, RN
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2002, 8 (02) : 167 - 173
  • [26] Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial.
    Ma, Jun
    Tang, Ling-Long
    Guo, Rui
    Zhang, Ning
    Deng, Bin
    Zhang, Yuan
    Huang, Jing
    Zhou, Guan-Qun
    Hu, Weihan
    Mao, Yan-Ping
    Li, Wen-Fei
    Liu, Qing
    Xie, Fangyun
    Sun, Ying
    Chen, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial
    Li, Guoming
    Yuan, Mei
    Li, Haihong
    Deng, Changsheng
    Wang, Qi
    Tang, Yexiao
    Zhang, Hongying
    Yu, Weisheng
    Xu, Qin
    Zou, Yuanyuan
    Yuan, Yueming
    Guo, Jiawen
    Jin, Chunming
    Guan, Xiangdong
    Xie, Fengjie
    Song, Jianping
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
  • [28] Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial
    de Jong, Evelien
    van Oers, Jos A.
    Beishuizen, Albertus
    Vos, Piet
    Vermeijden, Wytze J.
    Haas, Lenneke E.
    Loef, Bert G.
    Dormans, Tom
    van Melsen, Gertrude C.
    Kluiters, Yvette C.
    Kemperman, Hans
    van den Elsen, Maarten J.
    Schouten, Jeroen A.
    Streefkerk, Joern O.
    Krabbe, Hans G.
    Kieft, Hans
    Kluge, Georg H.
    van Dam, Veerle C.
    van Pelt, Joost
    Bormans, Laura
    Otten, Martine Bokelman
    Reidinga, Auke C.
    Endeman, Henrik
    Twisk, Jos W.
    van de Garde, Ewoudt M. W.
    de Smet, Anne Marie G. A.
    Kesecioglu, Jozef
    Girbes, Armand R.
    Nijsten, Maarten W.
    de lange, Dylan W.
    LANCET INFECTIOUS DISEASES, 2016, 16 (07): : 819 - 827
  • [29] The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: An open-label multicenter clinical study
    Taniguchi, Fuminori
    Ota, Ikuko
    Iba, Yumiko
    Toda, Toshiko
    Tagashira, Yukiko
    Ohata, Yorie
    Kurioka, Hiroko
    Endo, Yusuke
    Sunada, Hiroshi
    Noma, Hisashi
    Azuma, Yukihiro
    Harada, Tasuku
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2019, 45 (01) : 168 - 175
  • [30] An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis
    Elewski, Boni E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB87 - AB87